Escalation with overdose control using ordinal toxicity grades for cancer phase I clinical trials
type: Item
instance of: scholarly article
title: Escalation with overdose control using ordinal toxicity grades for cancer phase I clinical trials
zbMATH Open document ID: 1282.62235
DOI: 10.1155/2012/317634
author: Mourad Tighiouart
author: Galen Cook-Wiens
author: André Rogatko
published in: Journal of Probability and Statistics
publication date: 2013-01-09T00:00:00Z
review text: Summary: We extend a Bayesian adaptive phase I clinical trial design known as escalation with overdose control (EWOC) by introducing an intermediate grade 2 toxicity when assessing dose-limiting toxicity (DLT). Under the proportional odds model assumption of dose-toxicity relationship, we prove that in the absence of DLT, the dose allocated to the next patient given that the previously treated patient had a maximum of grade 2 toxicity is lower than the dose given to the next patient had the previously treated patient exhibited a grade 0 or 1 toxicity at the most. Further, we prove that the coherence properties of EWOC are preserved. Simulation results show that the safety of the trial is not compromised and the efficiency of the estimate of the maximum tolerated dose (MTD) is maintained relative to EWOC treating DLT as a binary outcome and that fewer patients are overdosed using this design when the true MTD is close to the minimum dose.
Mathematics Subject Classification ID: 62P10
Mathematics Subject Classification ID: 62L05
Mathematics Subject Classification ID: 62F15
zbMATH DE Number: 6123617
Wikidata QID: Q58910958
describes a project that uses: WinBUGS
MaRDI profile type: Publication
full work available at URL: https://doi.org/10.1155/2012/317634
OpenAlex ID: W2137656264
cites work: Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer
cites work: Q4284864
cites work: Optimal Bayesian-feasible dose escalation for cancer phase I trials
cites work: A Curve‐Free Method for Phase I Clinical Trials
cites work: Bayesian Nonparametric Inference on the Dose Level with Specified Response Rate
cites work: Bayesian Optimal Designs for Phase I Clinical Trials
cites work: Continual Reassessment Method: A Likelihood Approach
cites work: Sequential Designs for Phase I Clinical Trials with Late‐Onset Toxicities
cites work: Dose finding with escalation with overdose control (EWOC) in cancer clinical trials
cites work: Dose finding in drug development.
cites work: Statistical Methods for Dose‐Finding Experiments
cites work: Designs foe phase i cancer clinical trials with differentiation of graded toxicity
cites work: Dose-Finding Based on Multiple Toxicities in a Soft Tissue Sarcoma Trial
cites work: The Continual Reassessment Method for Multiple Toxicity Grades: A Bayesian Quasi‐Likelihood Approach
cites work: Risk-Group-Specific Dose Finding Based on an Average Toxicity Score
cites work: Monte Carlo sampling methods using Markov chains and their applications
cites work: Coherence principles in dose-finding studies
description: scientific article; zbMATH DE number 6123617